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Soluble forms of the trimeric human immunodeficiency virus (HIV-1) envelope glycoproteins are important tools for structural studies
and in the construction of improved immunogens. We found that a substantial fraction of soluble envelope glycoprotein trimers contain inter-
subunit disulfide bonds (inter-S–S bonds) that render the trimers resistant to heat and denaturing agents. These inter-S–S bonds can be
reduced without disrupting the trimers by treatment with a low concentration of h-mercaptoethanol or DTT. Antibody mapping studies
suggest that the soluble HIV-1 envelope glycoprotein trimers lacking the inter-S–S bonds exhibit a conformation closer to that of the native
HIV-1 envelope glycoprotein complex. However, reducing these inter-S–S bonds had only modest effects on the inefficient elicitation of
neutralizing antibodies by the soluble trimers. These studies provide guidance in improving the resemblance of tractable, soluble forms of the
HIV-1 envelope glycoproteins to the native virion spikes.
D 2004 Elsevier Inc. All rights reserved.
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Human immunodeficiency virus type 1 (HIV-1) enters
target cells through the interaction of its envelope glyco-
proteins, gp120 and gp41, with the cellular receptors, CD4
and chemokine receptors (Chan and Kim, 1998; Eckert and
Kim, 2001; Sodroski, 1999; Wyatt and Sodroski, 1998). In
infected cells, the envelope glycoproteins are synthesized as
an approximately 850-amino acid precursor, which is
extensively glycosylated in the endoplasmic reticulum to
create the gp160 envelope glycoprotein (Earl et al., 1990,
1991). The gp160 glycoprotein assembles into trimers and is
cleaved in the Golgi complex by a cellular protease to
generate the mature envelope glycoproteins: the exterior
(gp120) and the transmembrane (gp41) glycoproteins. The0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.11.013
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complex by virtue of noncovalent interactions with the
gp41 ectodomain. The trimeric complexes of gp120–gp41
heterodimers are transported to the cell surface and
incorporated into the viral envelope. The envelope glyco-
proteins are the sole viral components that are exposed on
the virion surface and that can potentially serve as the
targets for HIV-1-neutralizing antibodies. Therefore, the
HIV-1 envelope glycoproteins are the principal vaccine
candidates in attempts to elicit neutralizing antibodies.
It has been difficult to induce neutralizing antibody
responses against primary HIV-1 strains by using mono-
meric gp120 as an immunogen (Barnett et al., 1997; Belshe
et al., 1998; Berman et al., 1992; Burton and Moore, 1998;
Connor et al., 1998; Graham et al., 1998; Mascola et al.,
1996; Parren et al., 1999; Rusche et al., 1987; VanCott et al.,
1999; Wrin and Nunberg, 1994). Antibodies induced by
monomeric gp120 immunization apparently bind only
weakly to the functional trimeric HIV-1 envelope glyco-
proteins, even though monomeric gp120 is recognized05) 369–383
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1998). This suggests that there are significant structural and
conformational differences between the HIV-1 envelope
glycoprotein trimers and the monomeric gp120. In an
attempt to mimic the native HIV-1 envelope glycoprotein
trimers, soluble gp140() glycoproteins have been created
(Broder et al., 1994; Center et al., 2001, 2004; Chakrabarti
et al., 2002; Chen et al., 2000; Earl et al., 1990a, 1990b,
1994; Schulke et al., 2002; Srivastava et al., 2002; 2003a;
Stamatatos et al., 2000; Staropoli et al., 2000; VanCott et al.,
1997; Yang et al., 2000a, 2000b; Yang et al., 2002; Zhang et
al., 2001). These soluble gp140() glycoproteins consist of
the gp120 glycoprotein and the gp41 ectodomain, with
modifications at the gp120 and gp41 junction site to reduce
proteolytic cleavage. Preventing the proteolytic processing
of the soluble gp140 glycoproteins greatly contributes to the
stability of the oligomeric association of these molecules.
Soluble gp140() glycoproteins have been created based on
the envelope glycoproteins of a few primary HIV-1 strains
and SIV. These soluble gp140() glycoproteins are reported
to form dimers, trimers, and tetramers in addition to
monomers; the trimeric forms of gp140() can be partially
purified by chromatographic approaches (Barackman et al.,
2004; Center et al., 2004; Chen et al., 2000; Srivastava et
al., 2003a, 2002; Yang et al., 2000a, 2000b, 2002; Zhang et
al., 2001). Addition of trimerization motifs from the GCN4
transcription factor or from the T4 bacteriophage fibritin to
the carboxyl terminus of the HIV-1 gp140() glycoprotein
stabilizes the envelope glycoprotein trimers (Yang et al.,
2000a, 2000b, 2002). These soluble envelope glycoprotein
trimers are recognized better by neutralizing compared with
nonneutralizing antibodies (Fouts et al., 1997, 1998; Yang et
al., 2002), suggesting that the overall architecture of these
soluble trimers resembles that of the native envelope
glycoproteins. Some differences in epitope exposure on
the soluble trimers and mature, cell-surface envelope
glycoproteins can be attributed to the lack of gp120–gp41
proteolytic cleavage (Si et al., 2003). Soluble trimers are
more effective in eliciting HIV-1-neutralizing antibodies
than monomeric gp120 but are still too inefficient in this
capacity to be practically useful as a vaccine immunogen
(Barnett et al., 2001; Earl et al., 2001; Srivastava et al.,
2003b; Yang et al., 2001).
The atomic structure of the core HIV-1 gp120 monomer
has been solved in a complex with a soluble form of CD4
and a Fab fragment of a CD4-induced antibody (Kwong et
al., 1998). However, the native conformation of the trimeric
HIV-1 envelope glycoproteins still remains undetermined.
The preparation of soluble forms of the trimeric HIV-1
envelope glycoproteins is crucial for structural studies and
may be valuable in the design and construction of improved
vaccine immunogens. In this study, we examine the
oligomeric state of soluble gp140() glycoproteins by
quantitative cross-linking with glutaraldehyde (GA) and
report that sgp140() glycoproteins from different clade B
strains of HIV-1 form trimers, dimers, and higher orderaggregates. We found that a substantial fraction of
sgp140() trimers contain inter-subunit disulfide bonds
(inter-S–S bonds), which were dependent upon the integrity
of the C-terminal half of the gp41 ectodomain. Inter-S–S
bonds were also observed in a fraction of native, membrane-
bound HIV-1 envelope glycoproteins. We investigate the
contribution of these inter-S–S bonds to the antigenicity,
immunogenicity, and virus entry functions of the HIV-1
envelope glycoproteins.Results
Oligomeric state of soluble gp140()
The sgp140() glycoprotein contains the complete HIV-
1 gp120 and gp41 ectodomain sequences; alteration of the
gp120–gp41 junction prevents the proteolytic cleavage of
this molecule. To examine the oligomeric state of the
sgp140() glycoprotein, the most versatile cross-linking
agent, glutaraldehyde (GA), was employed. Treatment with
GA usually produces the fully cross-linked protein in high
yield, allowing a quantitative representation of the various
oligomeric complexes present in solution (Kyte, 1995). The
sgp140(/GCN4) glycoprotein from the YU2 strain of HIV-
1, which has already been shown to form stable trimers
(Yang et al., 2000a), was used to determine the conditions
for quantitative cross-linking with GA. As shown in Fig.
1A, without cross-linking, the HIV-1 YU2 sgp140(/
GCN4) appeared as monomers when analyzed by reducing
SDS-PAGE. At low concentrations of GA (0.5, 1, and 2
mM), the subunits in a complex were partially cross-linked
to each other, resulting in a ladder of trimers, dimers, and
monomers. Increasing the concentration of GA beyond 2
mM resulted in the cross-linking proceeding to completion,
with the majority of the sgp140(/GCN4) migrating at a
size consistent with that of a trimer on the reducing SDS-
polyacrylamide gel (Fig. 1A). This suggested that GA at a
concentration above 5 mM would fully cross-link all
subunits in a complex under the current experimental
conditions. To ensure that cross-linking proceeded to
completion, we used GA at concentrations up to 10 mM
in the following studies.
The oligomeric state of sgp140() from the YU2 HIV-1
strain was first investigated, and the gp120 glycoprotein
from this strain was analyzed in parallel as a control.
Following treatment with 10 mM GA, the YU2 sgp140()
glycoprotein migrated at sizes consistent with those of
trimers and dimers, whereas gp120 remained as a monomer
(Fig. 1B). This suggests that the sgp140() glycoprotein is
mostly trimeric, with some dimers. Similar results were
obtained with another cross-linking agent, ethylglycol
bis(sulfosuccinimidylsuccinate) (Sulfo-EGS) (Fig. 1C).
To corroborate the cross-linking results, the YU2
sgp140(/GCN4), sgp140(), and gp120 glycoprotein were
individually analyzed by 10–25% continuous sucrose
Fig. 1. Cross-linking of soluble envelope glycoproteins with GA. Radiolabeled sgp140(/GCN4) (A), sgp140(), and gp120 (B) glycoproteins from the YU2
strain of HIV-1 were cross-linked with varying concentrations of GA before being immunoprecipitated by PS and protein A–sepharose 4B. The precipitates
were subjected to reducing SDS-PAGE and autoradiography. The results of similar experiments with sulfo-EGS as a cross-linker are shown in C.
W. Yuan et al. / Virology 332 (2005) 369–383 371gradient centrifugation. The envelope glycoproteins were
then precipitated from gradient fractions with pooled sera
(PS) from HIV-1-infected individuals (Fig. 2A) and the
glycoprotein bands quantified with Phosphor Screen (Fig.
2B). The sgp140(/GCN4), which served as a marker for
trimers, peaked in gradient fraction 6; whereas gp120, which
served as an approximate marker for monomers, peaked inFig. 2. Sucrose density gradient analysis of HIV-1 envelope glycoproteins. (A) R
were analyzed individually by centrifugation on 10–25% continuous sucrose den
Envelope glycoproteins in each fraction were immunoprecipitated by PS and prote
(B) The radiolabeled glycoprotein bands in panel Awere quantified by Phosphor S
glycoproteins in sucrose gradient fractions 1–12 were cross-linked with 10 mM of G
subjected to SDS-PAGE and autoradiography.fractions 11–12. The sgp140() sedimented more slowly
than the sgp140(/GCN4) trimers, peaking in fraction 7 in
the gradient (Figs. 2A and B). To elucidate its oligomeric
state, the sgp140(), along with the sgp140(/GCN4), in
gradient fractions 1–12 was analyzed by cross-linking with
10 mM GA (Fig. 2C). The sgp140(/GCN4) glycoprotein in
the peak fractions 5–7 appeared to be trimers. Theadiolabeled YU2 sgp140(/GCN4), sgp140(), and gp120 glycoproteins
sity gradients, which were fractionated from the bottom of the gradients.
in A–sepharose 4B, followed by reducing SDS-PAGE and autoradiography.
creen and the amount of protein in each band graphed. (C) The radiolabeled
A before being immunoprecipitated by PS and protein A–sepharose 4B and
Fig. 3. Oligomeric state of sgp140(). (A) Radiolabeled sgp140()
glycoproteins from different HIV-1 strains were cross-linked with 1 or 10
mM GA followed by immunoprecipitation with PS and protein A–
sepharose 4B. The precipitates were subjected to SDS-PAGE and auto-
radiography. (B) The radiolabeled trimer, dimer, and monomer bands cross-
linked by treatment with 10 mM GA on the SDS-PAGE gel in A were
quantified by Phosphor Screen and graphed as a percentage of the total
soluble envelope glycoproteins.
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and dimers, with trimers evident in fractions 5–9 and dimers
evident in fractions 8–11. Fractions 3–5 contained a more
slowly migrating form, possibly a tetramer, of sgp140().
Trace amounts of the sgp140() glycoprotein monomers
were also seen in fraction 12 of the gradient (Fig. 2C). A
portion of both sgp140(/GCN4) and sgp140() glycopro-
teins formed higher order aggregates larger than trimers,
which migrated to the bottom fractions of the sucrose
gradients. These aggregates were also observed to stack on
the top of the lanes of SDS-PAGE gels when the
glycoproteins were cross-linked with GA. However, aggre-
gates were not observed for the gp120 glycoproteins (Fig.
1B). The data from the sucrose gradients support the
conclusion that the YU2 sgp140() glycoproteins form
trimers, dimers, and higher order structures. As has been
previously reported (Yang et al., 2000a), the addition of the
GCN4 trimeric motif in the sgp140(/GCN4) glycoprotein
increases the proportion of trimers formed and maintained
under these conditions.
Oligomeric state of sgp140() glycoproteins from different
HIV-1 strains
The oligomeric states of sgp140() glycoproteins from
several HIV-1 clade B strains were also examined by
cross-linking with 10 mM GA (Fig. 3). Similar to the YU2
sgp140() glycoprotein, the sgp140() glycoproteins from
JR-FL, ADA, HXBc2, and 89.6 strains of HIV-1 all
formed trimers and dimers. Monomeric sgp140() glyco-
proteins from these strains were slightly more abundant at
high GA concentrations than was seen with the YU2
sgp140() glycoprotein. The proportion of trimer, dimer,
and monomer differed somewhat among the sgp140()
glycoproteins from distinct HIV-1 strains (Fig. 3A).
Similar results were obtained with 50 mM GA, indicating
that these differences were not simply a result of different
sensitivity to the cross-linker (data not shown). The
amounts of trimeric, dimeric, and monomeric forms of
sgp140() observed after treatment with 10 mM GA from
these HIV-1 strains were quantified by Phosphor Screen
and the proportion of these forms is shown in Fig. 3B. The
proportion of sgp140() that forms trimers ranged from
40% to above 60%, with the YU2 protein exhibiting the
highest proportion (61.6%) of trimers. The proportion of
dimers ranged from 20% to 40%, with the ADA proteins
exhibiting the lowest levels. The proportion of monomers
ranged from below 10% to 35%, with the YU2 protein
exhibiting the lowest proportion (7.2%) (Fig. 2B). All of
the sgp140() glycoproteins formed some aggregates,
which stacked on the top of lanes of the SDS-polyacry-
lamide gel. We conclude that the formation of trimers and
dimers is a general property of sgp140() glycoproteins
from different HIV-1 strains, which exhibit some differ-
ences in the proportions of the different oligomeric states
formed.Soluble gp140() trimers contain inter-subunit disulfide
bonds
The native trimeric HIV-1 envelope glycoproteins com-
plexes consist of three heterodimers of gp120 and gp41. All
six subunits in the trimers are thought to be noncovalently
associated. However, when the sgp140() glycoproteins
from HIV-1 clade B strains were examined by nonreducing
SDS-PAGE and immunoblotting with PS, a substantial
portion of the glycoproteins remained as trimers and dimers
(Fig. 4A). As these samples were boiled for 10 min in the
presence of 1% of SDS before loading onto the gel, the
observed trimers and dimers are resistant to SDS and heat
treatment. Upon reduction with h-mercaptoethanol, these
dimers and trimers migrated as monomers (Fig. 4A). These
results suggest that the stability of these oligomeric forms of
sgp140() is dependent upon disulfide bonds.
To examine further the stability of these SDS- and heat-
resistant trimers and dimers, the YU2 sgp140() glyco-
protein, along with the sgp140(/GCN4) and sgp140(/
FT) glycoproteins, were boiled in the presence of 3 or 6 M
urea and 1% SDS before nonreducing SDS-PAGE and
immunoblotting. SDS- and heat-resistant trimers and
Fig. 4. Inter-subunit disulfide bonds in sgp140 trimers. (A) Transiently
expressed sgp140() glycoproteins from different HIV-1 strains were
analyzed by SDS-PAGE in the presence (+) or absence () of 1% h-
mercaptoethanol, followed by immunoblotting with PS and an HRP-
conjugated goat-anti-human Ig secondary antibody. (B) The YU2
sgp140(), sgp140(/GCN4), and sgp140(/FT) glycoproteins were
boiled in 1% SDS and up to 6 M urea for 10 min (left panel). The YU2
sgp140(/GCN4) glycoproteins were boiled in 1% SDS for up to 2 h (right
panel). The proteins were then analyzed by nonreducing SDS-PAGE and
immunoblotting. (C) The YU2 sgp140(/GCN4) glycoproteins were boiled
in 1% SDS in the presence of varying concentrations of h-mercaptoethanol
or DTT before being analyzed by SDS-PAGE and immunoblotting.
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left panel). A slightly greater proportion of trimers was
seen for the sgp140(/GCN4) and sgp140(/FT) glyco-
proteins than for the sgp140() glycoprotein; dimers were
more abundant than trimers for the latter protein. The
results indicate that these trimers and dimers can resist
even high concentrations of a chaotropic agent. The degree
of heat resistance was also tested by boiling the sgp140(/
GCN4) glycoproteins in 1% SDS for up to 2 h. As shownin the right panel of Fig. 4B, a portion of the glycoproteins
still remained associated as trimers and dimers after boiling
for 30 and even 60 min. By contrast, the SDS- and heat-
resistant trimers and dimers were very sensitive to
reducing agents; they were completely disrupted if boiled
in 1% SDS with the addition of as little as 0.01% h-
mercaptoethanol or 1 mM DTT (Fig. 4C). These data
indicate that the SDS- and heat-resistant trimers and dimers
contain inter-subunit disulfide bonds (herein designated as
binter-S–S bondsQ). The trimers and dimers that contain
one or more of these inter-S–S bonds comprise a
substantial fraction of the total proportion of oligomers
formed. This conclusion is based on a comparison of the
proportion of these proteins that form heat- and SDS-
resistant oligomers and the proportion of these proteins
that exist as oligomers, as documented in the cross-linking
experiments. Furthermore, as the proportion of heat- and
SDS-stable dimers is higher than the proportion of these
glycoproteins documented to be dimers in the cross-linking
experiments, some of the trimers must contain inter-S–S
bonds involving only two of the subunits.
Basis for the formation of inter-S–S bonds in HIV-1
envelope glycoprotein
Several possible reasons for the formation of inter-S–S
bonds in the HIV-1 envelope glycoproteins were inves-
tigated. The YU2 sgp140() glycoproteins analyzed above
were codon-optimized for expression in mammalian cells
and contain a CD5 signal sequence to increase the level of
expression and secretion. To investigate whether these
factors contribute to the formation of inter-S–S bonds, the
gp140(/GCN4) glycoproteins from the YU2 and HXBc2
HIV-1 strains with natural coding sequences and HIV-1
Env signal peptides were compared with their codon-
optimized counterparts with CD5 signal sequences. The
former glycoproteins also contained the SDS- and heat-
resistant trimers and dimers when analyzed by nonreduc-
ing SDS-PAGE and immunoblotting (Fig. 5A). The effects
of the protein expression levels on the formation of the
inter-S–S bonds were also examined by reducing the
amount of the transfected envelope glycoprotein-express-
ing plasmids. Although this resulted in the expected
decrease in the total amount of expressed envelope
glycoproteins, the proportion of SDS- and heat-resistant
trimers and dimers formed was unchanged (data not
shown). We conclude that neither the expression level
nor the presence of a heterologous signal peptide account
for the formation of the inter-S–S bonds in the soluble
HIV-1 envelope glycoprotein trimers.
The native HIV-1 envelope glycoproteins are produced by
cleavage of the gp160 precursor by a cellular protease before
transport to the cell surface, and are anchored in the viral or
cellular membrane by the gp41 transmembrane domains. In
the sgp140() glycoprotein and its derivatives, the site of
proteolytic cleavage is altered and the C-terminal part of
Fig. 5. Potential variables associated with the formation of inter-S–S bonds.
(A) YU2 or HXBc2 sgp140(/GCN4) glycoproteins expressed from
codon-optimized (co) or non-codon-optimized (nco) DNA sequences were
boiled in the presence or absence of 1% h-mercaptoethanol for the
indicated times before being analyzed by SDS-PAGE and immunoblotting
with PS and an HRP-conjugated goat-anti-human Ig secondary antibody.
(B) The YU2 sgp140(/FT), sgp140DV1/2(/FT), and sgp130DV1/2(/
FT) glycoproteins were boiled in the presence or absence of 1% h-
mercaptoethanol for the indicated times before being analyzed by SDS-
PAGE and immunoblotting as in A above.
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investigate the effects of these changes on the formation of
inter-S–S bonds, the YU2 sgp140(+/GCN4) glycoprotein,
which is identical to the sgp140(/GCN4) glycoprotein
except that the gp120/gp41 proteolytic cleavage site is intact
in the former protein, was analyzed. We also analyzed the
YU2 and HXBc2 gp160()DCTand gp160(+)DCT proteins,
which are membrane anchored and contain either an intact (+)
or altered () gp120/gp41 proteolytic cleavage site. Even
when this cleavage site is intact, some glycoproteins escape
proteolytic cleavage in the transient expression system used.
This allows the SDS- and heat-resistant oligomers to be easily
detected on nonreducing SDS-polyacrylamide gels. The
uncleaved sgp140(+/GCN4) and the membrane-associated
gp160DCT glycoproteins were found to contain SDS- and
heat-resistant trimers and dimers (data not shown). Thus, the
formation of inter-S–S bonds does not depend upon thealteration of the gp120–gp41 cleavage site or the deletion of
the membrane-spanning region.
The gp120 glycoproteins do not oligomerize when
expressed in tissue cultured cells, which indicates that the
gp41 ectodomain sequences are critical for the formation
of the inter-S–S bonds. The gp41 ectodomain could
contribute to inter-S–S bond formation by stabilizing the
trimeric or dimeric association of the subunits. In addition,
there are two cysteine residues in the gp41 ectodomain,
which naturally form a disulfide bond within the subunit.
To investigate whether these cysteine residues contribute to
the inter-S–S bond in the sgp140() glycoproteins, we
compared the efficiency of inter-S–S bond formation in
soluble trimeric envelope glycoproteins that retain or lack
the gp41 ectodomain region containing the pair of
cysteines. As intermolecular disulfide bonds dependent
on the V1/V2 stem-loop sequences have been observed in
some expression systems (Center et al., 2000), we used
envelope glycoproteins with V1/V2 deletions in this study.
The sgp130DV1/2(/FT) glycoprotein, which does not
contain the gp41 ectodomain region surrounding the two
cysteines, was expressed and analyzed by nonreducing
SDS-PAGE and immunoblotting. The sgp140(/FT) and
sgp140DV1/2(/FT) glycoproteins were analyzed in par-
allel. The sgp140(/FT) and sgp140DV1/2(/FT) glyco-
proteins contained SDS- and heat-resistant trimers and
dimers; in fact, the majority of the sgp140DV1/2(/FT)
glycoprotein contained inter-S–S bonds (Fig. 5B). By
contrast, the sgp130DV1/2(/FT) contained only trace
amounts of SDS- and heat-resistant dimers; most of the
gp130DV1/2(/FT) apparently lacked inter-S–S bonds.
Cross-linking the sgp140DV1/2(/FT) and sgp130DV1/
2(/FT) glycoproteins with GA demonstrated that both
glycoproteins exist as trimers (data not shown), as has
been previously demonstrated (Yang et al., 2000a, 2000b,
2002). Thus, the observed difference in the degree of inter-
S–S bond formation between these glycoproteins is not
simply a secondary consequence of inefficient oligomeri-
zation of the sgp130DV1/2(/FT) glycoprotein. We con-
clude that sequences in the C-terminal portion of the gp41
ectodomain contribute greatly to the efficiency with which
inter-S–S bonds are formed in soluble gp140 glycopro-
teins. These data are consistent with the possibility that the
cysteine residues in the gp41ectodomain contribute directly
to the formation of the inter-S–S bonds in the sgp140()
trimers.
Preparative reduction of the inter-subunit disulfide bonds in
the envelope glycoprotein trimer
To be able to investigate the consequences of the inter-S–
S bonds on the phenotype of the HIV-1 envelope
glycoproteins, these bonds needed to be reduced. The
reducing agents h-mercaptoethanol and DTT were
employed for this purpose. The YU2 sgp140(/GCN4)
trimers were incubated with varying concentrations of h-
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followed by dialysis against PBS to remove the reducing
agent. The treated sgp140(/GCN4) trimers were then
examined by nonreducing SDS-PAGE and immunoblotting;
this analysis demonstrated that 0.5% h-mercaptoethanol or
10 mM DTT were the lowest concentrations of these
reducing agents that were able to reduce the inter-S–S
bonds (data not shown). The sgp140(/GCN4) trimers that
were treated with 0.5% h-mercaptoethanol and dialyzed to
remove the reducing agent contained only a small fraction
of SDS- and heat-resistant dimers (Fig. 6). The treated
sgp140(/GCN4) glycoproteins still remained almost
exclusively trimeric, as evidenced by cross-linking with
10 mM GA (Fig. 6). Thus, pretreatment with 0.5% h-
mercaptoethanol reduced most of the inter-S–S bonds in the
YU2 sgp140(/GCN4) glycoproteins but did not disrupt the
trimerization of these molecules. The same experiment was
performed with the YU2 gp140() glycoprotein, with
similar results (data not shown).
Effects of the inter-S–S bonds on the antigenicity of the
soluble HIV-1 envelope glycoproteins
We wished to investigate the effects of the inter-S–S
bonds on the conformation of soluble envelope glycoprotein
trimers. Several monoclonal antibodies that recognize
different epitopes on the HIV-1 envelope glycoproteins
were tested for their ability to bind to the YU2 gp140(/
GCN4) trimers, which were either treated with h-mercap-
toethanol to reduce the inter-S–S bonds or left untreated.
The monoclonal antibodies used in this study included one
antibody, 2G12, that binds glycans on the gp120 outer
domain (Sanders et al., 2002; Scanlan et al., 2002); three
CD4-binding site antibodies: IgG1b12, F105, and F91Fig. 6. Reduction of inter-S–S bonds in sgp140(/GCN4) trimers. The
YU2 sgp140(/GCN4) glycoprotein was treated with 0.5% h-mercaptoe-
thanol at room temperature for 30 min, followed by continuous dialysis
against PBS overnight. The treated glycoproteins were cross-linked with 1
or 10 mM of GA. The glycoproteins were analyzed by SDS-PAGE in the
presence (+) or absence () of 1% h-mercaptoethanol, followed by
immunoblotting with PS and an HRP-conjugated goat-anti-human Ig
secondary antibody.(Moore and Sodroski, 1996); two CD4-induced antibodies:
17b and 48d (Moore and Sodroski, 1996; Xiang et al.,
2002); three nonneutralizing antibodies, C11, A32, 2/11c,
that recognize discontinuous gp120 epitopes (Moore and
Sodroski, 1996); and the gp41-directed neutralizing anti-
body, 2F5 (Muster et al., 1993). The CD4-Ig protein, which
consists of a fusion between the amino-terminal two
domains of CD4 and the immunoglobulin constant region
(Capon et al., 1989), was also used in this study (Fig. 7A).
The binding of the antibodies and the CD4-Ig protein to the
sgp140(/GCN4) glycoprotein was examined by ELISA.
The reduction of inter-S–S bonds had little effect on the
binding of the 2G12, IgG1b12, F105, F91, and 2F5
antibodies or the CD4-Ig protein (Fig. 7A). However, the
binding of CD4-induced antibodies 17b and 48d and the
binding of antibodies C11, A32, and 2/11c were decreased
when the inter-S–S bonds in the sgp140(/GCN4) glyco-
protein were reduced (Fig. 7A). The effects of mild
treatment with a reducing agent on the recognition of
gp120 by CD4-Ig and antibodies were tested by performing
a similar ELISA experiment with h-mercaptoethanol-treated
or untreated YU2 gp120 glycoproteins (Fig. 7B). All
monoclonal antibodies tested showed similar binding to
treated or untreated gp120 glycoproteins (Fig. 7B). Thus,
the inter-S–S bonds in the sgp140(/GCN4) glycoprotein
apparently contribute to the exposure of the CD4-induced
region and the gp120 epitopes recognized by the C11, A32,
and 2/11c antibodies.
Effects of the inter-subunit disulfide bonds on elicitation of
neutralizing antibodies
The antibody interaction data suggested that the inter-S–
S bonds can affect some structural features of the
sgp140(/GCN4) trimers. To test if this structural differ-
ence affects the ability of the soluble envelope glycopro-
tein trimers to elicit neutralizing antibodies, BALB/c mice
were immunized with YU2 sgp140(/FT) trimers with or
without reduction of the inter-S–S bonds. The purified
YU2 gp140(/FT) trimers used for immunization appeared
as a homogeneous peak on a Superose 6 gel-filtration
column; this glycoprotein ran as a single band with a
molecular weight of about 140 kDa on a reducing SDS-
polyacrylamide gel but contained the SDS- and heat-
resistant trimers and dimers when analyzed by nonreducing
SDS-PAGE (data not shown). The YU2 sgp140(/FT)
trimers, with or without the reduction of inter-S–S bonds,
the purified YU2 gp120 glycoprotein, and bovine serum
albumin (BSA) were inoculated into BALB/c mice to elicit
antibodies. A conservative immunization scheme was used
to increase sensitivity to any enhancement of immunoge-
nicity associated with reduction of the disulfide bonds. The
sera raised by the immunizations were examined for gp120
reactivity and neutralizing capability. The YU2 sgp140(/
FT) trimers, with or without reduction of the inter-S–S
bonds, elicited similar titers of antibodies reactive with the
Fig. 7. Effects of inter-S–S on antibody recognition of soluble envelope glycoproteins. The inter-S–S bonds in the YU2 sgp140(/GCN4) trimers (A) were
reduced by treatment with 0.5% h-mercaptoethanol and dialysis. In parallel, the YU2 gp120 glycoprotein was treated identically. Treated or untreated
sgp140(/GCN4) (A) or gp120 (B) glycoproteins were captured on ELISA plates by a sheep antibody D7324, followed by incubation with varying
concentrations of a panel of monoclonal antibodies and CD4-Ig. The antibodies and CD4-Ig bound to sgp140(/GCN4) or gp120 on the ELISA plates were
detected with an HRP-conjugated goat-anti-human Ig secondary antibody, followed by development with TMB substrates. Triangles with dashed lines
represent sgp140(/GCN4) trimers or gp120 glycoproteins without h-ME pretreatment. Diamonds with solid lines represent sgp140(/GCN4) trimers or
gp120 glycoproteins with h-ME pretreatment.
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positive signals at 1:12800 to 1:51200 dilutions. The
capability of the sera to neutralize HIV-1 infection wasexamined using a single-round infection assay with
recombinant HIV-1 encoding luciferase and containing
YU2 or HXBc2 envelope glycoproteins. All the sera from
W. Yuan et al. / Virology 332 (2005) 369–383 377the mice immunized with sgp140(/FT) trimers, with or
without reduction of the inter-S–S bonds, exhibited very
mild neutralization activity to either the homologous YU2
virus or heterologous HXBc2 virus (Fig. 8). For the
homologous YU2 virus, the sera raised from immunization
with the sgp140(/FT) glycoproteins treated with h-
mercaptoethanol neutralized virus infection slightly better
than those from animals immunized with untreated
sgp140(/FT) trimers (Fig. 8). For the heterologous
HXBc2 virus, sera from animals immunized with untreated
sgp140(/FT) demonstrated slightly better inhibition than
those from animals immunized with h-mercaptoethanol-
treated sgp140(/FT). Although only low levels of
neutralizing antibodies were elicited by this conservative
immunization scheme, it appears that reduction of the
inter-S–S bonds in the sgp140(/FT) envelope glycopro-
teins exerted only a small impact on the elicitation of
neutralizing antibodies.
Effects of the inter-subunit disulfide bonds on virus entry
Our studies and those of others (Owens and Compans,
1990) indicate that inter-S–S bonds exist in the mem-
brane-anchored envelope glycoproteins of recombinant
HIV-1 viruses. These bonds, as was seen for the inter-
S–S bonds in the soluble gp140 glycoproteins, can be
reduced by incubating the virus with 0.5% h-mercaptoe-
thanol followed by continuous dialysis (data not shown).
To test the effects of the inter-S–S bonds on viral entry,
recombinant HIV-1 encoding luciferase and containing
YU2 HIV-1 envelope glycoproteins with deleted cyto-
plasmic tails was prepared. It has been suggested thatFig. 8. Effects of inter-S–S bonds on the elicitation of neutralizing antibodies. Th
treatment with 0.5% h-mercaptoethanol and dialysis (140-R), gp120 (120), and
inactivated at 558C for 1 h and then diluted 20- or 40-fold with growth medium (
HIV-1 encoding luciferase and containing YU2 or HXBc2 envelope glycoproteins
expressing CD4 and either CCR5 or CXCR4 coreceptors. After incubation at 37
activity in the target cells was measured 2 days later. The relative infectivity of
incubated with antisera to that of the virus incubated with serum raised by BSA im
with antisera from individual mice. Bars represent the means of the virus infectivprotein disulfide isomerase (PDI) on the target cell
membrane might mediate a thiol–disulfide interchange in
the viral envelope glycoproteins during HIV-1 entry
(Barbouche et al., 2003; Fenouillet et al., 2001; Gallina
et al., 2002; Markovic et al., 2004; Ryser et al., 1994). As
this activity might impact the potential phenotype of inter-
S–S bonds in the HIV-1 envelope glycoproteins, we
conducted the entry assays in the absence or presence of
inhibitors of PDI. In one approach to inhibiting the
function of PDI, a membrane-impermeant sulfhydryl
reagent, 5,5V-dithiobis(2-nitrobenzoic acid) (DTNB), was
used to treat the Cf2Th-CD4/CCR5 target cells for 15
min prior to virus infection; the recombinant viruses were
incubated with the target cells for 2 h in the presence of
DTNB before washing the cells and replacing the
medium. As shown in Fig. 9A, treatment with low
concentrations of h-mercaptoethanol had little effect on
the infectivity of recombinant HIV-1 viruses. The entry of
both treated and untreated recombinant viruses with the
YU2 HIV-1 envelope glycoproteins decreased with the
addition of increasing concentrations of DTNB. However,
the entry of the control recombinant virus containing the
VSV-G envelope glycoproteins also decreased, indicating
that the DTNB effect was not specific for the viruses with
HIV-1 envelope glycoproteins. Thus, it does not appear
that the inter-S–S bonds in the envelope glycoproteins of
recombinant HIV-1 viruses exert a significant impact on
virus entry.
In a second approach to inhibiting PDI function,
infections were carried out in the presence of increasing
concentrations of bacitracin, a PDI inhibitor. The effects of
bacitracin on virus infection were specific for viruses withe untreated YU2 sgp140(/FT) trimers (140), sgp140(/FT) trimers after
BSA were used to immunize mice. Antisera raised in the mice were heat-
20 and 40, respectively). The antisera were incubated with recombinant
for 2 h at 378C. The virus–antibody mixture was then added to target cells
8C for 2 h, the cells were suspended in growth medium, and the luciferase
the virus was calculated by comparing the luciferase activity of the virus
munization. Open diamonds represent the virus infectivity after incubation
ity in the same group.
Fig. 9. Effects of inter-S–S bonds on virus entry. Recombinant HIV-1
encoding luciferase and containing the YU2 envelope glycoproteins with
deleted gp41 cytoplasmic tails was treated with 0.5% h-mercaptoethanol
and continuous dialysis. Cf2Th-CD4/CCR5 target cells were treated with
varying concentrations of DTNB for 15 min prior to virus infection (A).
The h-mercaptoethanol-pretreated viruses [YU2(+)], untreated viruses
[YU2()], and recombinant viruses containing VSV-G envelope glyco-
proteins (VSV-G) were incubated with target cells in the presence of
varying concentrations of DTNB for 2 h. The cells were then washed and
resuspended in growth medium. The luciferase activity in the target cells
was measured 2 days later. In B, the above recombinant viruses were added
to target cells in the presence of the indicated concentrations of bacitracin.
Luciferase activity in the target cells was measured as described above.
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viruses with h-mercaptoethanol did not significantly affect
their infectivity.Discussion
Soluble forms of the trimeric HIV-1 envelope glycopro-
teins are important tools for structural characterization of
these molecules as well as for immunogen design. The poor
stability of soluble HIV-1 envelope glycoprotein oligomers
has necessitated either alteration of the gp120/gp41 proteo-
lytic cleavage site or the introduction of artificial disulfide
bonds in gp120 and gp41 to covalently link the subunits
(Binley et al., 2000; Sanders et al., 2000; Schulke et al.,
2002). Even with these modifications, significant hetero-
geneity characterizes the oligomers consisting of HIV-1
envelope glycoprotein ectodomains. These oligomers have
been examined by sucrose density gradient analysis, gelfiltration chromatography, analytical ultracentrifugation,
blue native PAGE, and chemical cross-linking. Several
methods have revealed not only trimers for these sgp140()
molecules, but also dimers and higher-order forms, possibly
including tetramers (Chakrabarti et al., 2002; Earl et al.,
1994; Schulke et al., 2002; Staropoli et al., 2000; Zhang et
al., 2001). Our results indicate that this propensity to form
heterogeneous oligomers is a property common to the
envelope glycoprotein ectodomains of several HIV-1 strains.
The ability to form both the presumably more native trimers
and the potentially artefactual dimers and aggregates
depends upon the integrity of the gp41 ectodomain in the
soluble glycoproteins (Earl and Moss, 1993; Schulke et al.,
2002; Yang et al., 2000b). The gp120 glycoprotein is very
soluble and demonstrates little tendency to self-associate,
further supporting the contribution of gp41 to the formation
of intermolecular aggregates.
The heterogeneity of sgp140() preparations renders the
purification and study of the trimeric forms difficult
(Barackman et al., 2004). By increasing the proportion of
soluble gp140 glycoproteins that are in a trimeric state, the
addition of trimerization motifs from GCN4 or fibritin
circumvents many problems in purification (Yang et al.,
2000a, 2000b, 2002).
A substantial fraction of soluble gp140 glycoproteins and
a smaller fraction of membrane-anchored HIV-1 envelope
glycoproteins contain inter-S–S bonds. Inter-S–S bonds
have been previously noted in soluble (Schulke et al., 2002)
and membrane-bound, full-length HIV-1 envelope glyco-
proteins (Owens and Compans, 1990). In our study, inter-S–
S bonds were observed in the sgp140() glycoproteins from
several HIV-1 strains, indicating that the structural charac-
teristics leading to the formation of these disulfide bonds are
conserved. The formation of inter-S–S bonds depended
upon the integrity of the C-terminal half of the gp41
ectodomain, which contains a pair of cysteines that are well-
conserved among retroviral transmembrane envelope gly-
coproteins. These cysteines are thought to participate in an
intramolecular disulfide bond. It is possible that one or both
of these cysteines instead participate in an inter-S–S bond in
a fraction of the HIV-1 envelope glycoproteins. It is also
possible that the C-terminal portion of the gp41 ectodomain
subtly influences the oligomeric associations involved in
stabilizing the trimer and thus indirectly allows the inter-S–
S bonds to form.
Gentle reduction followed by removal of the reducing
agent resulted in loss of more than 90% of the inter-S–S
bonds present in the sgp140(/GCN4) trimers. All of the
discontinuous epitopes examined remained intact after this
treatment, indicating that no major perturbation of the native
conformation of the HIV-1 envelope glycoproteins resulted
from this treatment. Of note, transient treatment with
reducing agents resulted in a decrease in recognition by
the A32, 211/C, and C11 antibodies. The gp120 epitopes
recognized by these antibodies are thought to be poorly
exposed/available on the functional HIV-1 envelope glyco-
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According to current models of the HIV-1 envelope
glycoproteins, the gp120 surfaces involved in these epitopes
are near the trimer axis and may be buried as a result of
interactions with gp41 or other gp120 subunits (Wyatt et al.,
1998). Gentle reduction of the inter-S–S bonds also resulted
in a decrease in recognition by the 17b and 48d antibodies.
As antibody binding to these epitopes is CD4 induced (Thali
et al., 1993), these structures are likewise thought to be
relatively inaccessible on the functional envelope glycopro-
tein trimer prior to CD4 engagement (Sullivan et al., 1998).
Thus, the observed decrease in recognition by both of these
groups of antibodies might indicate that the sgp140(/
GCN4) glycoprotein achieves better mimicry of the func-
tional HIV-1 envelope glycoproteins after the inter-S–S
bonds are reduced. These observed decreases are specifi-
cally associated with the trimer, as the gp120 monomer
treated similarly with reducing agents did not exhibit
disruption of these epitopes.
Based on the better resemblance of the soluble gp140
trimers with the inter-S–S bonds reduced to the functional
HIV-1 envelope glycoproteins, the contribution of this bond
reduction to the immunogenicity of the soluble trimers was
investigated. The conservative immunization schedule used
did not reveal any advantage of the sgp140(/FT) glyco-
proteins over monomeric gp120 in eliciting neutralizing
antibodies. With multiple immunizations, soluble stabilized
trimers elicit qualitatively and quantitatively better neutraliz-
ing antibody responses than gp120 (Barnett et al., 2001; Earl
et al., 2001; Srivastava et al., 2003b; Yang et al., 2001). Our
results emphasize that the neutralizing antibodies raised by
either of these immunogens are still low in titer and breadth;
these immunogens will need considerable improvement to
make them suitable as vaccine components. Of some interest
is the observation that the sgp140(/FT) glycoprotein with
reduced inter-S–S bonds elicited antibodies that neutralized
the homologous YU2 HIV-1 isolate better than the heterol-
ogous HXBc2 HIV-1 isolate. This is particularly noteworthy
in light of the relative sensitivity of the HXBc2 virus to
neutralization compared with the YU2 strain of HIV-1. The
results raise the possibility that even bona fide mimics of
functional envelope glycoprotein complexes from primary
HIV-1 isolates may preferentially elicit strain-restricted
neutralizing antibodies.
Inter-S–S bonds were observed in membrane-anchored
HIV-1 envelope glycoproteins with the potential to be
proteolytically processed to mature, functional products. As
only a small fraction of the total amount of the HIV-1
envelope glycoproteins synthesized needs to function to
allow virus entry, we cannot ascertain whether envelope
glycoproteins with inter-S–S bonds might retain function.
We observed little effect of exposing HIV-1 virions to
reducing agents on the infectivity of the virus preparations.
Our results leave open the possibility that inter-S–S bonds
form only in a functionally defective subset of HIV-1
envelope glycoproteins, an interpretation favored by otherinvestigators studying inter-S–S bonds in full-length HIV-1
envelope glycoproteins (Owens and Compans, 1990).
Our findings should encourage greater awareness of
potential inter-S–S bonds in preparations of soluble HIV-1
envelope glycoprotein trimers and attention to the possible
effects of these bonds on the properties of the proteins. Our
method of reducing these bonds while preserving the overall
architecture of the trimers should be useful in future
structural and immunological studies of these important
HIV-1 components.Materials and methods
Envelope plasmid constructs
The envelope glycoproteins in this study were produced
by the pSVIIIenv expression plasmids (Sullivan et al., 1995).
The sgp140() glycoproteins consist of the complete gp120
and gp41 ectodomains and contain alterations in the gp120/
gp41 proteolytic cleavage site (arginines at amino acid
positions 508 and 511 changed to serines). The sgp140(/
GCN4) or sgp140(/FT) constructs contain the sgp140()
sequence with a GCN4 or fibritin trimerization motif,
respectively, appended to the carboxyl terminus of the gp41
ectodomain (Yang et al., 2000a, 2000b). The sgp140(+/
GCN4) construct is identical to sgp140(/GCN4) except that
the gp120/gp41 proteolytic cleavage site is intact. The
sgp130(/FT) plasmid was constructed by appending the
fibritin trimerization motif after leucine 593 of the cleavage-
defective envelope glycoprotein. The sgp140DV1/2(/FT)
and sgp130DV1/2(/FT) constructs contain a Gly-Ala-Gly
linker in place of the V1/V2 loop (amino acid residues 120–
203) in the sgp140(/FT) or sgp130(/FT) constructs,
respectively. The gp160DCT expression plasmids were
constructed by introducing a stop codon after the coding
region for the gp41 transmembrane domain (at the codon for
tyrosine 712) in the pSVIIIenv plasmids. Amino acid
numbers correspond to those of the prototypic HXBc2
HIV-1 envelope glycoproteins, as per current convention
(Kuiken et al., 2002). The ADA sgp140() expression
construct was made by replacing the KpnI to BsmI fragment
of the pSVIIIenv plasmid with the equivalent fragment from
the ADA strain (Sullivan et al., 1995); the encoded envelope
glycoproteins contain the HXBc2 sequence in the gp41
region encompassing amino acid residues 613–683.
Cross-linking of oligomeric soluble gp140
The envelope glycoproteins were produced transiently in
293T cells and radiolabeled with [35S]-methionine, as
previously described (Yang et al., 2000a, 2000b). After
clearance of the cell debris by low-speed centrifugation, the
culture supernatant was brought to a final concentration of 1
mM EDTA and incubated with varying concentrations of
GA (Sigma, St. Louis, MO) at room temperature for 5 min,
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fold higher than that of GA to quench the unreacted GA.
The cross-linked glycoproteins were then immunoprecipi-
tated by a mixture of pooled sera (PS) from HIV-1-infected
individuals and protein A–sepharose beads (Pharmacia).
The precipitates were analyzed by SDS-PAGE under
reducing conditions with precast 3–8% Tris–acetate gels
(Invitrogen), followed by autoradiography.
Envelope glycoproteins transiently expressed in the
supernatants of transfected 293T cells were also cross-
linked with sulfo-EGS (Pierce). The radiolabeled cell
supernatants were incubated with varying concentrations
of sulfo-EGS at room temperature for 30 min, followed by
addition of glycine to quench the unreacted sulfo-EGS. The
cross-linked envelope glycoproteins were precipitated and
analyzed as described above.
Sucrose density gradient centrifugation
Approximately 400 Al of radiolabeled supernatant con-
taining transiently expressed sgp140() glycoproteins were
loaded on an 11-ml 10–25% continuous sucrose gradient
and centrifuged in a Beckman SW41 rotor for 20 h at
36,000 rpm at 4 8C. Fractions of approximately 0.6 ml each
were collected from the bottom of the gradients, and the
glycoproteins in the fractions were immunoprecipitated by
PS and protein A–sepharose beads, followed by analysis by
reducing SDS-PAGE. The sgp140() bands on the gels
were quantified with a Phosphor Screen and Storm 820
scanner (Molecular Dynamics, Sunnyvale, CA).
Immunoblot detection of envelope glycoproteins
The 293T cell supernatants containing transiently
expressed, unlabeled sgp140 glycoproteins were mixed
with 2 SDS-PAGE sample buffer, either in the presence
(reducing) or in the absence (nonreducing) of 1% h-
mercaptoethanol, and subjected to SDS-PAGE.
The 293T cells expressing gp160DCT glycoproteins
were lysed with PBS containing 1% NP-40 and Protease
Inhibitor Cocktail (Roche) at 4 8C for 1 h before
centrifuging at 13,000  g for 30 min at 4 8C. The cell
lysates were mixed with 2 SDS-PAGE sample buffer and
subjected to SDS-PAGE.
After electrophoresis, the proteins in the gel were
transferred to a 0.22-Am nitrocellulose membrane, and the
envelope glycoproteins were probed with PS, followed by
detection with a horseradish peroxidase (HRP)-conjugated
goat-anti-human Ig secondary antibody (Sigma) and devel-
opment with ECL substrates (Pierce).
Reduction of the inter-subunit disulfide bonds of soluble
gp140() trimers
The 293T cell supernatants containing envelope glyco-
proteins, or purified sgp140(/FT) trimer proteins, wereincubated with 0.5% h-mercaptoethanol for 30 min at room
temperature, followed by continuous dialysis against phos-
phate-buffered saline (PBS) overnight at 4 8C.
Antibody interaction with soluble gp140() trimers
The antibody interaction with sgp140() trimers was
examined by ELISA. The sgp140(/GCN4) trimers from
the YU2 HIV-1 strain in the supernatant of transiently
expressing 293T cells were either mock treated or treated as
above to reduce the inter-subunit disulfide bonds. The
envelope glycoproteins were then captured on ELISA plates
by a sheep antibody (D7324) raised against the carboxyl
terminal 15 amino acid residues of HIV-1 gp120 (Cliniqa
Corp., Fallbrook, CA). Next, varying concentrations of a
panel of monoclonal antibodies that recognize different
envelope glycoprotein epitopes were added to the wells. The
antibodies bound to sgp140(/GCN4) on the ELISA plates
were detected with an HRP-conjugated goat-anti-human Ig
secondary antibody, followed by development with TMB
substrates (Sigma).
Immunization of mice and serum preparation
The immunogen, the HIV-1 YU2 sgp140(/FT) trimer
that contains a 6-histidine (His6) tag at the C-terminus of the
fibritin domain, was produced in a stably transfected CHO
cell line, and purified by a Ni-NTA (Qiagen) metal-chelating
affinity column followed by a Superose 6 gel-filtration
column (Amersham). The inter-S–S bonds in these trimers
were reduced as described above. The HIV-1 YU2 gp120
glycoprotein, which also contains a 6-histidine tag (His6)
fused to its C-terminus, was produced and purified by the
same scheme and used in parallel in the immunizations.
Bovine serum albumin (BSA) (Sigma) was used for
immunization as a negative control.
For immunizations, 10 Ag of immunogens [purified
sgp140(/FT) trimers, with or without reduction of inter-
subunit disulfide bonds, purified gp120, and BSA] were
mixed with 1 Ribi adjuvant (Sigma) in a final volume of
200 Al of PBS and injected subcutaneously into each of five
Balb/c female mice. Inoculations were administered at the
ages of 7, 11, and 15 weeks. Eye bleeding was performed at
14 days after the final inoculation. Following clot formation
overnight at 4 8C, the samples were centrifuged at 13,000 
g for 10 min and the sera were collected and stored at 20
8C. Before the neutralization assay, the sera were incubated
at 55 8C for 1 h to inactivate complement.
HIV-1 neutralization assay
The HIV-1-neutralizating activity of the sera was
examined by a single-round infection assay as previously
described (Yang et al., 2001). Briefly, recombinant HIV-1
encoding luciferase and containing various HIV-1 envelope
glycoproteins was incubated with sera at a certain dilution in
W. Yuan et al. / Virology 332 (2005) 369–383 381growth medium for 2 h at 37 8C before adding to either
Cf2Th-CD4/CXCR4 or Cf2Th-CD4/CCR5 target cells.
Cf2Th-CD4/CXCR4 cells were used for viruses with the
HXBc2 envelope glycoproteins, and Cf2Th-CD4/CCR5
cells were used for viruses with the YU2 envelope
glycoproteins. The virus-serum mixture was incubated with
cells at 37 8C in 5% CO2 for 2 h and then replaced with
growth medium. The luciferase activity in the target cells
was measured 2 days later. The residual infectivity of the
virus was calculated by comparing the luciferase activity of
the virus incubated with a test serum to that of the virus
incubated with serum raised by BSA immunization.Acknowledgments
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